Read twice and referred to the Committee on Finance. (text: CR S3119)
This bill amends the Social Security Act’s Drug Price Negotiation Program orphan-drug exclusion. It (1) prevents periods when a drug had orphan status from counting toward elapsed-time calculations used to determine negotiation eligibility, and (2) expands the orphan exclusion language to cover drugs approved for one or more rare diseases or conditions (cross-referencing the FD&C Act definition).
Progressives emphasize higher costs and weakened negotiation powers.
Relative to its intended legislative type, this bill constitutes a focused substantive change to the Drug Price Negotiation Program by amending statutory language to exclude periods when a drug had orphan status from elapsed-time calculations and by broadening the definition language for rare diseases/conditions.
This bill amends the Social Security Act’s Drug Price Negotiation Program orphan-drug exclusion.
It (1) prevents periods when a drug had orphan status from counting toward elapsed-time calculations used to determine negotiation eligibility, and (2) expands the orphan exclusion language to cover drugs approved for one or more rare diseases or conditions (cross-referencing the FD&C Act definition).
A narrow, administrable change helps prospects, but contentious subject (drug pricing), fiscal implications, and lack of compromise features reduce likelihood.
Relative to its intended legislative type, this bill constitutes a focused substantive change to the Drug Price Negotiation Program by amending statutory language to exclude periods when a drug had orphan status from elapsed-time calculations and by broadening the definition language for rare diseases/conditions. The amendments are specific and clearly referenced to existing statutory text.
Progressives emphasize higher costs and weakened negotiation powers.
These are examples from the analysis, not a ranked list of the most-affected groups.
Progressives emphasize higher costs and weakened negotiation powers.
Likely to view the bill negatively because it narrows Medicare negotiation reach and may prolong higher drug prices.
It acknowledges rare-disease development concerns but is seen as favoring manufacturers more than patients or federal cost containment.
Views the bill as a targeted technical fix with tradeoffs: it better protects incentives for rare-disease therapies but risks increasing negotiation exclusions and costs.
Support depends on safeguards, cost estimates, and implementation details.
Likely to support the bill as it strengthens protections for orphan drugs and limits government price-setting reach.
Seen as pro-innovation and reducing regulatory penalties for developing rare-disease treatments.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
A narrow, administrable change helps prospects, but contentious subject (drug pricing), fiscal implications, and lack of compromise features reduce likelihood.
The bill has not accumulated any surfaced votes yet.
Progressives emphasize higher costs and weakened negotiation powers.
A narrow, administrable change helps prospects, but contentious subject (drug pricing), fiscal implications, and lack of compromise feature…
Relative to its intended legislative type, this bill constitutes a focused substantive change to the Drug Price Negotiation Program by amending statutory language to exclude periods when a drug had orphan status from el…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.